Osteoporosis thins bones until they break easily, most often in the hip, spine, and wrist. Most treatments slow bone loss; a smaller group, the bone-building or osteoanabolic drugs, add new bone, and the main ones are peptides related to parathyroid hormone (PTH), such as teriparatide and abaloparatide, given as daily injections.
Much of the site's coverage follows efforts to make those peptides easier to take. Entera Bio plans a 750-patient Phase 3 trial of EB613, an oral PTH(1-34) tablet, in postmenopausal women, with total hip bone density as the main measure, and at ENDO 2026 it reported a single tablet performing comparably to injected teriparatide. In October 2026, Chinese chemists reported fatty-acid versions of teriparatide that lasted longer in blood in lab and animal tests.
See #teriparatide and our guide to peptides for osteoporosis.
Researchers at Shandong University and the Shandong Academy of Pharmaceutical Science reported in the Journal of Medicinal Chemistry on October 16, 2026 that they used a site-specific chemical ligation method to attach fatty acids of different lengths to teriparatide, the bone-building osteoporosis drug that must be injected daily. Of 12 lipidated versions, four matched native teriparatide's bone-building activity in lab and animal tests, and the lead compound, called 62, was markedly more stable in serum. The goal is a longer-acting osteoporosis injection; the work is preclinical.
Entera Bio (Nasdaq: ENTX) presented full single-tablet EB613 results on June 14 at ENDO 2026 in Chicago as a late-breaking oral. The single-tablet EB613 achieved a comparable pharmacokinetic and pharmacodynamic profile to Forteo (injectable teriparatide) and to the multi-tablet EB613 used in Entera's earlier Phase 2 study in postmenopausal women with osteoporosis. On the administration-experience quality-of-life questionnaire, 14 of 15 study participants preferred the single tablet to the multi-tablet format, and all 15 preferred the daily oral EB613 to the daily injection. Entera plans to advance the single-tablet formulation into the Phase 3 trial in 750 postmenopausal women starting late 2026, with topline expected H2 2028.
Entera Bio (Nasdaq: ENTX) confirmed that its first-in-class oral PTH(1-34) tablet EB613 was selected for a late-breaking oral presentation at ENDO 2026 covering single-tablet data ahead of the 750-patient Phase 3 trial set to start late 2026 in postmenopausal osteoporosis. EB613 applies Entera's N-Tab oral-peptide delivery platform to teriparatide (the active ingredient in Forteo). On the obesity side, Entera will present preclinical PK/PD data on EB618, a first-in-class oral dual GLP-1/glucagon receptor agonist, in non-human primates on Saturday June 13 12:15-1:45 PM CT. The ENDO slot extends Entera's spring narrative beyond the Q1 2026 Phase 3 plan first disclosed in May.
Entera Bio reported Q1 2026 May 8 with $20.4M cash and an updated Phase 3 plan for EB613, an oral once-daily PTH(1-34) tablet that would be the first oral osteoanabolic for postmenopausal osteoporosis. The streamlined Phase 3 protocol — submitted to the FDA in March — covers 750 postmenopausal women with primary endpoint of total hip BMD change from baseline at month 12. Trial initiation is targeted for late 2026, with topline H2 2028 — roughly one year earlier than previously guided. The molecule applies Entera's N-Tab oral peptide platform to teriparatide, the active ingredient in Forteo. The Phase 2 dose-ranging study in 161 patients met primary (PD/bone-turnover biomarker) and secondary (BMD) endpoints.